BRK-B vs HIVE
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
HIVE exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While the company shows explosive revenue growth (218.60% YoY) and trades slightly below book value (P/B 0.90), these are offset by deep negative profit margins (-48.63%) and a complete lack of technical momentum (Technical Trend: 0/100). The massive divergence between the 'Strong Buy' analyst consensus and the actual financial health suggests a speculative valuation based on future potential rather than current performance.
Compare Another Pair
Related Comparisons
BRK-B vs HIVE: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and HIVE Digital Technologies Ltd. (HIVE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.